Nivolumab rechallenge after pituitary apoplexy associated with nivolumab plus ipilimumab in a patient with pituitary adenoma and rectal melanoma: a case report and literature review
Abstract Background The overall incidence of pituitary apoplexy among patients with pituitary adenoma ranges from 0.6% to 7.0%, although many cases likely go undiagnosed. Several precipitating factors have been identified, and a small number of case reports have suggested an association between immu...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMC
2026-03-01
|
| Collection: | Journal of Pharmaceutical Health Care and Sciences |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1186/s40780-026-00564-4 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|